[Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease].
It is well known now that hypolipidemic therapy is able to inhibit development of atherosclerosis. This decreases the rate of coronary complications. However, the problem of adequate pharmacotherapy duration has not been solved yet, as long-term treatment may provoke side effects. This study compared efficacy of hyperlipidemia (HLE) correction by long-term hypolipidemic diet (HD) and pharmacotherapy (PT) in patients with ischemic heart disease (IHD). 93 HLE patients with IHD aged 50-65 years entered the study. Enduracin used for 16-24 weeks (Endurance Products Company, USA) in a dose 1500 mg/day has reduced cholesterol by 15.7%, low density lipoproteins--by 19.2%, triglycerides--by 26%. High density lipoproteins rose by 15.7%. Besafibrat (Germany) in a dose 600 mg/day is indicated for patients with isolated hypertriglyceridemia (reduced triglycerides by 41.2%). Enduracin is indicated for patients with moderate levels of atherogenic serum lipids in isolated and combined HLE if fibrates are contraindicated. Diet lowered LDLP and VLDLP insignificantly and did not change HDLP. Prolongation of diet did not enhance the effect this allowing using diet therapy as background treatment.
Mal'
G S
GS
D000368:Aged; D001629:Bezafibrate / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000178:diet therapy* / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000175:diagnosis; D009525:Niacin / Q000627:therapeutic use*; D013997:Time Factors
D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D009525:Niacin; D001629:Bezafibrate